XML 59 R48.htm IDEA: XBRL DOCUMENT
v3.25.2

DISCONTINUED OPERATIONS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement | $ 0 | $ 302 | $ 0 | $ 1,275
Transaction Services [Member] | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 0 |  |
Mundipharma | Total revenues | Rezafungin | Related Party | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 21,573 |  | 28,670
Mundipharma | Rezafungin Assets, including Sale of Intellectual Property and Inventory | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 20,833 |  | 20,833
Mundipharma | License of Intellectual Property - upon milestone achieved | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 0 |  | 813
Mundipharma | Product revenue | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 0 |  | 2,826
Mundipharma | Royalty Revenue | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 11 |  | 37
Mundipharma | Research and Development Services | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 629 |  | 3,895
Mundipharma | Clinical Supply Services | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 9 |  | 175
Mundipharma | Transaction Services [Member] | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 91 |  | 91
Melinta | Total revenues | Rezafungin | Related Party | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 189 |  | 582
Melinta | Rezafungin Assets, including Sale of Intellectual Property and Inventory | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 0 |  | 0
Melinta | License of Intellectual Property - upon milestone achieved | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 0 |  | 0
Melinta | Product revenue | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 0 |  | 0
Melinta | Royalty Revenue | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 49 |  | 125
Melinta | Research and Development Services | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | 140 |  | 457
Melinta | Clinical Supply Services | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  | $ 0 |  | 0
Melinta | Transaction Services [Member] | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue from collaborative agreement |  |  |  | $ 0

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_TransactionServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_RezafunginMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_RezafunginAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |